Financials Valneva SE Pref. Euronext Paris
Equities
VLAP
FR0011472943
Biotechnology & Medical Research
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% |
|
-7.89% | -28.57% |
Jul. 01 | Valneva's Secures Marketing Authorization in Europe for Chikungunya Vaccine | MT |
Jul. 01 | New semester, new state of mind | ![]() |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 233.7 | 704.9 | 2,574 | 861.1 | 655.1 | 478.1 | - | - |
Enterprise Value (EV) 1 | 195.5 | 553.9 | 2,286 | 670.5 | 737.8 | 533.9 | 564.5 | 587.5 |
P/E ratio | -129 x | -10.9 x | -32.7 x | -5.02 x | -6.47 x | 125 x | -37.1 x | -19.1 x |
Yield | - | - | - | - | - | - | 0.29% | - |
Capitalization / Revenue | 1.85 x | 6.39 x | 7.4 x | 2.38 x | 4.26 x | 2.69 x | 2.03 x | 1.44 x |
EV / Revenue | 1.55 x | 5.02 x | 6.57 x | 1.86 x | 4.8 x | 3.01 x | 2.4 x | 1.78 x |
EV / EBITDA | 25.1 x | -12.3 x | -48.5 x | -9.69 x | -11.3 x | 11.2 x | -22 x | -761 x |
EV / FCF | -36.5 x | 4.68 x | -140 x | -2.44 x | -3.4 x | 39 x | -96 x | -710 x |
FCF Yield | -2.74% | 21.4% | -0.71% | -41% | -29.4% | 2.56% | -1.04% | -0.14% |
Price to Book | 1.73 x | 9.09 x | 15.1 x | - | 5.1 x | 2.62 x | 3.85 x | 4.48 x |
Nbr of stocks (in thousands) | 90,920 | 90,958 | 105,078 | 138,355 | 138,788 | 139,153 | - | - |
Reference price 2 | 2.570 | 7.750 | 24.50 | 6.224 | 4.720 | 3.436 | 3.436 | 3.436 |
Announcement Date | 2/27/20 | 2/25/21 | 2/3/22 | 3/23/23 | 3/21/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 126.2 | 110.3 | 348.1 | 361.3 | 153.7 | 177.6 | 235.2 | 330.9 |
EBITDA 1 | 7.8 | -45.2 | -47.1 | -69.2 | -65.24 | 47.52 | -25.68 | -0.7722 |
EBIT 1 | -0.811 | -55.12 | -61.4 | -113.4 | -82.09 | 25.86 | -32.94 | -11.25 |
Operating Margin | -0.64% | -49.97% | -17.64% | -31.4% | -53.4% | 14.56% | -14.01% | -3.4% |
Earnings before Tax (EBT) 1 | -0.87 | -65.3 | -69.98 | -144.8 | -98.63 | -0.9092 | -47.79 | -18.11 |
Net income 1 | -1.7 | -64.4 | -73.4 | -143.3 | -101.4 | 0.7921 | -45.88 | -23.61 |
Net margin | -1.35% | -58.39% | -21.09% | -39.66% | -65.99% | 0.45% | -19.5% | -7.13% |
EPS 2 | -0.0200 | -0.7100 | -0.7500 | -1.240 | -0.7300 | 0.0275 | -0.0925 | -0.1800 |
Free Cash Flow 1 | -5.355 | 118.3 | -16.27 | -274.7 | -217 | 13.69 | -5.878 | -0.8273 |
FCF margin | -4.24% | 107.22% | -4.67% | -76.02% | -141.16% | 7.7% | -2.5% | -0.25% |
FCF Conversion (EBITDA) | - | - | - | - | - | 28.8% | - | - |
FCF Conversion (Net income) | - | - | - | - | - | 1,727.67% | - | - |
Dividend per Share 2 | - | - | - | - | - | - | 0.0100 | - |
Announcement Date | 2/27/20 | 2/25/21 | 2/3/22 | 3/23/23 | 3/21/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2020 S1 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 47.91 | 278.3 | 21.8 | 71.4 | 93.2 | 156.7 | 111.4 | 33.51 | 40.19 | 38.07 | 41.9 | 32.75 | 41.38 | 43.63 | 55.36 |
EBITDA | - | 12.54 | -13.3 | -122.7 | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -21.93 | 11.1 | -18.4 | -128.8 | -147.2 | 93.32 | -56.35 | -16.57 | -20.28 | -22.21 | -24.91 | 68.21 | -18.62 | -18.85 | -18.27 |
Operating Margin | -45.77% | 3.99% | -84.4% | -180.39% | -157.94% | 59.55% | -50.58% | -49.46% | -50.46% | -58.35% | -59.45% | 208.25% | -45% | -43.2% | -33% |
Earnings before Tax (EBT) 1 | - | - | - | - | - | - | - | - | - | - | - | - | -31.23 | -32.12 | -31.65 |
Net income 1 | - | - | - | - | - | - | - | - | - | - | - | - | -31.23 | -32.12 | -31.65 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | -75.48% | -73.62% | -57.17% |
EPS 2 | - | - | - | - | - | - | - | -0.1300 | -0.1200 | -0.2500 | -0.2300 | 0.4100 | -0.0800 | -0.1100 | -0.1000 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 8/4/20 | 2/3/22 | 5/5/22 | 8/11/22 | 8/11/22 | 11/10/22 | 3/23/23 | 5/4/23 | 9/21/23 | 11/9/23 | 3/21/24 | 5/7/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | 82.7 | 55.8 | 86.4 | 109 |
Net Cash position 1 | 38.1 | 151 | 289 | 191 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | -1.268 x | 1.174 x | -3.362 x | -141.6 x |
Free Cash Flow 1 | -5.36 | 118 | -16.3 | -275 | -217 | 13.7 | -5.88 | -0.83 |
ROE (net income / shareholders' equity) | -1.25% | -60.6% | -59.2% | -73.4% | -58.3% | -10.8% | -37.7% | -13.2% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | 1.490 | 0.8500 | 1.620 | - | 0.9300 | 1.310 | 0.8900 | 0.7700 |
Cash Flow per Share 2 | 0.0600 | 0.9500 | - | -0.8600 | - | -0.1000 | -0.1000 | 0.1000 |
Capex 1 | 10.5 | 18.9 | 92.2 | 29.2 | 14.2 | 13.7 | 11.7 | 9.55 |
Capex / Sales | 8.32% | 17.17% | 26.49% | 8.09% | 9.26% | 7.71% | 4.97% | 2.89% |
Announcement Date | 2/27/20 | 2/25/21 | 2/3/22 | 3/23/23 | 3/21/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- VLA Stock
- VLAP Stock
- Financials Valneva SE Pref.